MX9708124A - Derivados de toxina de botulinio capaces de modificar las funciones aferentes perifericas. - Google Patents

Derivados de toxina de botulinio capaces de modificar las funciones aferentes perifericas.

Info

Publication number
MX9708124A
MX9708124A MX9708124A MX9708124A MX9708124A MX 9708124 A MX9708124 A MX 9708124A MX 9708124 A MX9708124 A MX 9708124A MX 9708124 A MX9708124 A MX 9708124A MX 9708124 A MX9708124 A MX 9708124A
Authority
MX
Mexico
Prior art keywords
sensory afferent
botulinum toxin
peripheral sensory
toxin derivatives
modify peripheral
Prior art date
Application number
MX9708124A
Other languages
English (en)
Other versions
MXPA97008124A (es
Inventor
Keith Alan Foster
Michael John Duggan
Clifford Charles Shone
Original Assignee
Speywood Lab Ltd
Microbiological Res Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speywood Lab Ltd, Microbiological Res Authority filed Critical Speywood Lab Ltd
Publication of MX9708124A publication Critical patent/MX9708124A/es
Publication of MXPA97008124A publication Critical patent/MXPA97008124A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

La invencion se refiere a un agente específico para aferentes sensoriales periféricos. El agente puede inhibir la transmision de señales entre una aferente sensorial primaria y una neurona de proyeccion controlando la liberacion de, por lo menos, un neurotransmisor o neuromodulador del aferente sensorial primario. El agente se puede usar en o como un farmacéutico para el tratamiento de dolor, particularmente dolor cronico.
MXPA/A/1997/008124A 1995-04-21 1997-10-21 Derivados de toxina de botulinio capaces de modificar las funciones aferentes perifericas MXPA97008124A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9508204.6 1995-04-21
GBGB9508204.6A GB9508204D0 (en) 1995-04-21 1995-04-21 A novel agent able to modify peripheral afferent function

Publications (2)

Publication Number Publication Date
MX9708124A true MX9708124A (es) 1998-06-28
MXPA97008124A MXPA97008124A (es) 1998-10-30

Family

ID=

Also Published As

Publication number Publication date
AU705924B2 (en) 1999-06-03
DE69633228D1 (de) 2004-09-30
US8158132B2 (en) 2012-04-17
KR19990007943A (ko) 1999-01-25
WO1996033273A1 (en) 1996-10-24
JPH11504006A (ja) 1999-04-06
BR9609870A (pt) 1999-04-06
CA2218857C (en) 2010-05-25
US7892560B2 (en) 2011-02-22
US20030049264A1 (en) 2003-03-13
TR199701215T1 (xx) 1998-02-21
NO974845L (no) 1997-12-18
PT826051E (pt) 2004-11-30
US5989545A (en) 1999-11-23
US20060051356A1 (en) 2006-03-09
AU5339896A (en) 1996-11-07
US20120141511A1 (en) 2012-06-07
NO974845D0 (no) 1997-10-20
NZ305411A (en) 1999-11-29
CN1122718C (zh) 2003-10-01
CA2218857A1 (en) 1996-10-24
ES2225876T3 (es) 2005-03-16
US6395513B1 (en) 2002-05-28
DE69633228T2 (de) 2005-09-08
ATE274581T1 (de) 2004-09-15
ZA963129B (en) 1996-10-22
SG52602A1 (en) 1998-09-28
EP0826051A1 (en) 1998-03-04
US7887810B2 (en) 2011-02-15
HUP9802392A2 (hu) 1999-02-01
HUP9802392A3 (en) 2000-09-28
JP4304241B2 (ja) 2009-07-29
GB9508204D0 (en) 1995-06-07
SK143597A3 (en) 1998-09-09
US20080319167A1 (en) 2008-12-25
CZ332297A3 (cs) 1998-03-18
BG101984A (en) 1998-07-31
RU2165976C2 (ru) 2001-04-27
CN1187217A (zh) 1998-07-08
US20090131645A1 (en) 2009-05-21
PL323006A1 (en) 1998-03-02
US6962703B2 (en) 2005-11-08
EP0826051B1 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
NZ305411A (en) Clostridial toxin derivatives able to modify peripheral sensory afferent functions
EP1374886A3 (en) Treatment of neuromuscular disorders and conditions with different botulinum serotype
EP1421948A3 (en) Use of botulinum toxins for treating sweating in humans
CA2222303A1 (fr) Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
CA2171561A1 (en) K-252a Derivatives Which Enhance Neurotrophin-Induced Activity
EP0737442A4 (en) TEST PLASTER AND TEST METHOD
WO1999045949A3 (en) Use of follistatin to modulate gdf-8 and bmp-11
CA2296720A1 (en) Use of botulinum toxin in the preparation of a pharmaceutical composition for treating a prostate disorder in a mammal
NZ333588A (en) Sulphamates as anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
WO1996033724A3 (en) Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
GB9612862D0 (en) Method and device for controlling the brake system of a vehicle
MX9709238A (es) Formulaciones farmaceuticas y de dieta para la profilaxis y tratamiento de trastornos gastrointestinales.
GR3035702T3 (en) Pharmaceutical combination, containing a renin-angiotensin-system inhibitor and an endothelin antagonist.
WO2002026101A3 (en) System and method for the control of behavioral disorders
AU3902299A (en) Methods of treating microbial infection and therapeutic formulations therefor
EP0612057A3 (en) Active noise control systems.
WO2002009683A3 (en) Aldosterone blocker therapy to prevent or treat inflammation-related disorders
AU1628597A (en) Treatment and prophylaxis of pancreatitis
WO2000012045A3 (en) Method for treating neurodegenerative disorders
EP0661807A3 (en) Active adaptive regulation system with spectral leak signal.
AU2196297A (en) Methods of treating or preventing interstitial cystitis
AU7986798A (en) Method of enhancing magnesium absorption and prevention of atherosclerosis
EP0750912A3 (en) Batroxobin containing medicaments for the treatment or prophylaxis of ischemia-reperfusion injury
NO972607L (no) Sekvestreringsmidler
BG102087A (en) The use of pyrrolidine derivatives for the treatment of alcoholism